NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
December 24, 2024 — New study in Biomedical Analysis reviews advancements in detection of circRNAs, highlighting their potential as cancer biomarkers. Crucial for understanding disease processes and improving diagnosis and prognosis.
December 19, 2024 — Boost your immune system with iron - a crucial nutrient for maintaining a healthy immune system, especially during cold and flu season. Learn about the important role of iron in supporting immune health and the benefits of a highly absorbable iron supplement like Ferosom.
December 23, 2024 — Dr. Yorell Manon-Matos launches the Dr. Yorell Manon Matos Grant for Healthcare Students, offering a $1,000 award to support undergraduate students pursuing careers in healthcare. The grant aims to encourage those with a passion for addressing the complex challenges facing the healthcare industry today.
December 20, 2024 — Leonhardt Ventures LLC granted exclusive patent for bioelectric stimulator, a significant advancement in regenerative medicine. The core platform technology will be applied to various medical applications, including heart and cardiovascular health, brain health, major organ regeneration, medical aesthetics, and cancer treatment.
December 20, 2024 — Cognition Therapeutics Inc. announced positive topline results of its exploratory phase 2 SHIMMER study for CT1812, its experimental orally delivered small molecule oligomer antagonist to treat dementia with Lewy bodies, showing potential breakthrough in treatment.
December 20, 2024 — Mainz Biomed N.V. is on the brink of launching its early colorectal cancer detection screening ColoAlert® in the U.S. through strategic partnerships, potentially addressing the lack of timely screening for colorectal cancer and improving survival rates. The news highlights the importance of innovative diagnostic solutions and the significant market opportunity for Mainz Biomed in the U.S.
December 20, 2024 — Amesite's NurseMagic AI-Powered App is addressing the shortage of home healthcare workers in the U.S. with its innovative technology, bringing potential benefits for both workers and patients, and driving revenue growth for the company.
December 20, 2024 — apZme, Sleep Group Solutions, and Sleep Impressions partner with Tulia Dental to provide comprehensive sleep apnea treatment to patients in Texas, expanding access to care for individuals with sleep-related breathing disorders and improving health outcomes.
December 20, 2024 — Seeds for a Future is empowering Guatemalan families to break free from poverty and malnutrition with its sustainable program. By supporting the organization, readers can make a real difference in the lives of these families and their kids, helping them cultivate a brighter future for their communities.
December 20, 2024 — First nationwide class action lawsuit filed challenging Kaiser's Hearing Aid Exclusion. Impact on hearing disabled individuals seeking fair health insurance coverage.
December 19, 2024 — Clene Inc. (NASDAQ: CLNN) secures $10 million debt facility to support the development of its CNM-Au8 treatment for ALS and neurodegenerative diseases, addressing FDA data requirements for regulatory approval.
December 19, 2024 — Salignostics proudly announces the TGA approval of its revolutionary saliva-based pregnancy test, Salistick, marking a pivotal step forward for the company and the future of home diagnostics. This achievement reinforces the safety, quality, and performance of the non-invasive, accurate, and user-friendly solution, poised to redefine pregnancy testing and advance healthcare worldwide.
December 19, 2024 — apZme proudly announces the credentialing of Dr. John Taylor III to provide oral appliance therapy to Veterans in Baltimore. This achievement ensures access to non-invasive, high-quality sleep solutions for Veterans, supported by apZme, Sleep Impressions, Millennium Sleep Lab, and the VA.
December 18, 2024 — Discover the breakthrough oral care product, ioVet™ Oral, from ioTech International, designed to reduce dental plaque and promote healthier mouths in pets. Learn how this innovative solution can help prevent periodontal disease and its associated health consequences in canines and felines.
December 18, 2024 — Cure Alzheimer’s Fund achieves 100% perfect score and Four-Star rating from Charity Navigator for the 13th consecutive year, reflecting commitment to responsible stewardship and impactful research funding.
December 18, 2024 — Medical Supply Chain LLC revolutionizes healthcare procurement with its AI-driven platform, freeing markets from exorbitant single sources middlemen. The company's goal is to end the artificial inflation of hospital supply costs that has plagued the industry for the last 30 years.
December 17, 2024 — Salignostics, a leader in innovative saliva-based diagnostic solutions, proudly announces that its revolutionary saliva-based pregnancy test, Salistick, has received approval from Australia’s Therapeutic Goods Administration (TGA). This achievement marks a pivotal step forward for Salignostics, allowing the company to bring its cutting-edge technology to consumers in Australia and New Zealand. Partnering with SGG Solutions, the Australian sponsor for the product, Salignostics is poised to redefine pregnancy testing with its non-invasive, accurate, and user-friendly solution.
December 17, 2024 — SBC Medical Group Holdings expands its footprint in Asia and launches a new B2B wellness offering. The company's strategic growth initiatives position it for success in the expanding consumer and corporate wellness sectors.
December 17, 2024 — Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) secures $1 million in equity financing, positioning itself as an emerging leader in age-reversal science. The company's leading product, Telomir-1, shows promising age-reversal and longevity benefits in preclinical studies, capitalizing on the growing global market for age-related therapies.
December 17, 2024 — Benzinga reports on Soligenix Inc.'s potential breakthrough in treating the rare cancer, CTCL, with its lead product candidate, HyBryte. The news highlights the efficacy and safety of HyBryte in clinical studies, signaling hope for individuals living with mycosis fungoides.